Global Companion Diagnostics Partnering 2010-2018: Deal trends, players and financials
Trends in companion diagnostics partnering deals
Companion diagnostics partnering agreement structure
Companion diagnostics partnering contract documents
Top companion diagnostics deals by value
Most active companion diagnostics dealmakers
The report provides a detailed understanding and analysis of how and why companies enter Companion Diagnostics partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes.
This report provides details of the latest Companion Diagnostics agreements announced in the life sciences since 2010.
The report takes the reader through a comprehensive review Companion Diagnostics deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Companion Diagnostics partnering deals.
The report presents financial deal term values for Companion Diagnostics deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.
The middle section of the report explores the leading dealmakers in the Companion Diagnostics partnering field; both the leading deal values and most active Companion Diagnostics dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.
One of the key highlights of the report is that over 350 online deal records of actual Companion Diagnostics deals, as disclosed by the deal parties, are included towards the end of the report in a directory format by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.
In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered contract documents provide this insight where press releases and databases do not.
The initial chapters of this report provide an orientation of Companion Diagnostics dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Companion Diagnostics dealmaking since 2010, including details of headline, upfront, milestone and royalty terms.
Chapter 3 provides a review of the leading Companion Diagnostics deals since 2010. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive listing of the top 25 most active companies in Companion Diagnostics dealmaking with a brief summary followed by a comprehensive listing of Companion Diagnostics deals announded by that company, as well as contract documents, where available.
Chapter 5 provides a comprehensive and detailed review of Companion Diagnostics partnering deals signed and announced since Jan 2010, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive and detailed review of Companion Diagnostics partnering deals signed and announced since Jan 2010. The chapter is organized by specific Companion Diagnostics technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.
A comprehensive series of appendices is provided organized by Companion Diagnostics partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in Companion Diagnostics partnering and dealmaking since 2010.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Companion Diagnostics technologies and products.
Global Companion Diagnostics Partnering 2010-2018: Deal trends, players, financials and forecasts provides the reader with the following Key benefits
In-depth understanding of Companion Diagnostics deal trends since 2010
Access to headline, upfront, milestone and royalty data
Analysis of the structure of Companion Diagnostics agreements with numerous real life case studies
Detailed access to actual Companion Diagnostics contracts entered into by leading biopharma companies
Identify most active Companion Diagnostics dealmakers since 2010
Insight into terms included in a Companion Diagnostics partnering agreement, with real world examples
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Global Companion Diagnostics Partnering 2010-2018: Deal trends, players, financials and forecasts is intended to provide the reader with an in-depth understanding and access to Companion Diagnostics trends and structure of deals entered into by leading companies worldwide.
Companion Diagnostics Partnering Terms and Agreements includes:
Trends in Companion Diagnostics dealmaking in the biopharma industry since 2010
Analysis of Companion Diagnostics deal structure
Access to headline, upfront, milestone and royalty data
Case studies of real-life Companion Diagnostics deals
Access to Companion Diagnostics contract documents
Leading Companion Diagnostics deals by value since 2010
Most active Companion Diagnostics dealmakers since 2010
In GlobalCompanion Diagnostics Partnering 2010-2018: Deal trends, players, financials and forecasts, the available deals are listed by:
Stage of development at signing
Deal component type
Specific therapy target
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The Global Companion Diagnostics Partnering 2010-2018: Deal trends, players, financials and forecasts report provides comprehensive access to available deals and contract documents for over 350 Companion Diagnostics deals.
Analyzing actual contract agreements allows assessment of the following:
What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How aresalesand payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?
Chapter 1 Introduction
Chapter 2 Trends in Companion Diagnostics dealmaking
2.2. Companion Diagnostics partnering over the years
2.3. Most active Companion Diagnostics dealmakers
2.4. Companion Diagnostics partnering by deal type
2.5. Companion Diagnostics partnering by therapy area
2.6. Deal terms for Companion Diagnostics partnering
2.6.1 Companion Diagnostics partnering headline values
2.6.2 Companion Diagnostics deal upfront payments7
2.6.3 Companion Diagnostics deal milestone payments
2.6.4 Companion Diagnostics royalty rates
Chapter 3 Leading Companion Diagnostics deals
3.2. Top Companion Diagnostics deals by value
Chapter 4 Most active Companion Diagnostics dealmakers
4.2. Most active Companion Diagnostics dealmakers
4.3. Most active Companion Diagnostics partnering company profiles
Chapter 5 Companion Diagnostics contracts dealmaking directory
5.2. Companion Diagnostics contracts dealmaking directory
Chapter 6 Companion Diagnostics dealmaking by technology type
Chapter 7 Partnering resource center
7.1. Online partnering
7.2. Partnering events
7.3. Further reading on dealmaking
Appendix 1 Companion Diagnostics deals by company A-Z
Appendix 2 Companion Diagnostics deals by stage of development
Appendix 3 Companion Diagnostics deals by deal type
Appendix 4 Companion Diagnostics deals by therapy area
Appendix 5 Deal type definitions
About Wildwood Ventures
Recent report titles from Current Partnering
Table of figures
Figure 1: Companion Diagnostics partnering since 2010
Figure 2: Active Companion Diagnostics dealmaking activity since 2010
Figure 3: Companion Diagnostics partnering by deal type since 2010
Figure 4: Companion Diagnostics partnering by disease type since 2010
Figure 5: Companion Diagnostics deals with a headline value
Figure 6: Companion Diagnostics deals with an upfront value
Figure 7: Companion Diagnostics deals with a milestone value
Figure 8: Companion Diagnostics deals with a royalty rate value
Figure 9: Top Companion Diagnostics deals by value since 2010
Figure 10: Most active Companion Diagnostics dealmakers since 2010
Figure 11: Online partnering resources
Figure 12: Forthcoming partnering events
IntroductionAvascular necrosis is the death of the bone tissue due to a lack of blood supply and is also known as osteonecrosis. Avascular necrosis can lead to tiny breaks inView Report
2018 Global Thrombin Time Market: US, Europe, Japan--Volume and Sales Segmentation Forecasts, Competitive Landscape, Current Methods and Instrumentation, Opportunities for Suppliers
The growing cost-containment pressures in major industrialized nations and continued technological advances will radically change coagulation testing practice during the next five years. New specific and sensitive markers ofView Report
Global Next Generation Cancer Diagnostics Market Size Study, By Technology (NGS, LOAC & RT-PCR), By Application (CTC, Biomarker, Proteomic), By Cancer Type (Lung, Breast), By Function Companion Diagnostics) and Regional Forecasts, 2017-2025
Global Next Generation Cancer Diagnostics Market to reach USD 14.5 billion by 2025.Global Next Generation Cancer Diagnostics Market is valued approximately USD 5.8 billion in 2016 and is expected toView Report
Global Fluorescent In Situ Hybridization (FISH) Probe Market Size Study By Application (Genetic Diseases, and Cancer Research), By RNA Type (miRNA, mRNA, and Others), By End-Use (Clinical, Research, and Companion Diagnostics), and By Regional (North America, Europe, Asia Pacific, Latin America, and Rest of the World) Forecasts, 2018-2025
Global Fluorescent In Situ Hybridization (FISH) Probe Market to reach USD 976.1 million by 2025. Global Fluorescent In Situ Hybridization (FISH) Probe Market valued approximately USD 551.02 million in 2016View Report
Your are not allow to send sample request
Fill The Form For Sample Request